WorldCat Identities

Alitalo, Kari

Overview
Works: 20 works in 46 publications in 2 languages and 399 library holdings
Genres: Conference papers and proceedings 
Roles: Author, Speaker, Editor, Other
Publication Timeline
.
Most widely held works by Kari Alitalo
Synthetic peptides in biology and medicine : proceedings of the Labsystems Research Symposium on Synthetic Peptides in Biology and Medicine held in Hämeenlinna, Finland, on June 6-8, 1985 by Labsystems Research Symposium on Synthetic Peptides in Biology and Medicine( Book )

10 editions published between 1985 and 1986 in English and held by 163 WorldCat member libraries worldwide

Recombinant systems in protein expression : proceedings of the Labsystems Research Symposium II on Recombinant Systems in Protein Expression, Imatra, Finland, 23-26 July 1989 by Kari Alitalo( Book )

14 editions published in 1990 in English and Undetermined and held by 114 WorldCat member libraries worldwide

VEGF inhibitors for anti-angiogenic therapy by Kari Alitalo( Visual )

2 editions published in 2007 in English and held by 53 WorldCat member libraries worldwide

Audio-visual presentation : Antagonist monoclonal antibodies to VEGFR-3 ; Mode of action of antagonist monoclonal antibodies ; Functional properties of antagonist antibodies to VEGFR-3 ; In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis ; Inhibition of pathological vessel growth in the cornea ; Anti-angiogenic effect of antibodies to VEGFR-3 in tumors ; Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 ; Role of VEGFR-3 in normal and pathological immune response
The VEGF family by Kari Alitalo( Visual )

2 editions published in 2007 in English and held by 50 WorldCat member libraries worldwide

Audio-visual presentation : Vascular Endothelial Growth Factors (VEGF) ; Inhibition of VEGF action to control tumor angiogenesis ; VEGFs and VEGF receptor tyrosine kinases ; Structure of VEGF ; Signaling through a receptor tyrosine kinase ; Role of VEGFR-1 in angiogenesis ; Biological role of VEGF ; VEGF in embryonic angiogenesis ; Role of VEGF in physiological angiogenesis both during development and in the adult ; Roles of VEGFR-3 and VEGF-C in the early phases of development ; Mechanism of VEGF-C action in lymphatic development ; Tumor angiogenesis ; Result of overexpression of VEGF in tissues
Oncogene amplification( Book )

2 editions published in 1993 in English and held by 3 WorldCat member libraries worldwide

Biologia( Book )

2 editions published in 1998 in Finnish and held by 2 WorldCat member libraries worldwide

VEGF inhibitors for anti-angiogenic therapy by Kari Alitalo( Book )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

The VEGF Receptor Family by Kari Alitalo( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation : Vascular Endothelial Growth Factors (VEGF) - Inhibition of VEGF action to control tumor angiogenesis - VEGFs and VEGF receptor tyrosine kinases - Structure of VEGF - Signaling through a receptor tyrosine kinase - Role of VEGFR-1 in angiogenesis - Biological role of VEGF - VEGF in embryonic angiogenesis - Role of VEGF in physiological angiogenesis both during development and in the adult - Roles of VEGFR-3 and VEGF-C in the early phases of development - Mechanism of VEGF-C action in lymphatic development - Tumor angiogenesis - Result of overexpression of VEGF in tissues
Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract: Objective: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for Ang-2 in plaque stability. Despite the availability of Ang-2 blocking agents, their clinical use is still lacking. Our aim was to establish if Ang-2 has a role in atheroma development and in the transition of subclinical to clinically relevant atherosclerosis. We investigated the effect of antibody-mediated Ang-2 blockage on atherogenesis after in a mouse model of atherosclerosis. Methods: Hypercholesterolemic (low-density lipoprotein receptor −/− apolipoprotein B 100/100 ) mice were subjected to high-cholesterol diet for eight weeks, one group with and one group without Ang-2 blocking antibody treatment during weeks 4–8.To enhance plaque development, a peri-adventitial collar was placed around the carotid arteries at the start of antibody treatment. Aortic root, carotid arteries and brachiocephalic arteries were analyzed to evaluate the effect of Ang-2 blockage on atherosclerotic plaque size and stable plaque characteristics. Results: Anti-Ang-2 treatment reduced the size of fatty streaks in the brachiocephalic artery (−72%, p < 0.05). In addition, antibody-mediated Ang-2 blockage reduced plasma triglycerides (−27%, p < 0.05). In contrast, Ang-2 blockage did not have any effect on the size or composition (collagen content, macrophage percentage, adventitial microvessel density) of pre-existing plaques in the aortic root or collar-induced plaques in the carotid artery. Conclusions: Ang-2 blockage was beneficial as it decreased fatty streak formation and plasma triglyceride levels, but had no adverse effect on pre-existing atherosclerosis in hypercholesterolemic mice. Highlights: Antibody-mediated Ang-2 blockage delays fatty streak formation in mice. Ang-2 blockage lowers plasma triglyceride levels. Ang-2 blockage has no negative effects on preexisting atherosclerosis
VEGF inhibitors for anti-angiogenic therapy by Kari Alitalo( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response
Lymphatic System in Cardiovascular Medicine( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : The mammalian circulatory system comprises both the cardiovascular system and the lymphatic system. In contrast to the blood vascular circulation, the lymphatic system forms a unidirectional transit pathway from the extracellular space to the venous system. It actively regulates tissue fluid homeostasis, absorption of gastrointestinal lipids, and trafficking of antigen-presenting cells and lymphocytes to lymphoid organs and on to the systemic circulation. The cardinal manifestation of lymphatic malfunction is lymphedema. Recent research has implicated the lymphatic system in the pathogenesis of cardiovascular diseases including obesity and metabolic disease, dyslipidemia, inflammation, atherosclerosis, hypertension, and myocardial infarction. Here, we review the most recent advances in the field of lymphatic vascular biology, with a focus on cardiovascular disease
Syövän biologia( Book )

1 edition published in 1985 in Finnish and held by 1 WorldCat member library worldwide

Virustautien diagnostiset menetelmät : (virusopin laboratoriotyöt)( Book )

1 edition published in 1989 in Finnish and held by 1 WorldCat member library worldwide

The VEGF family by Kari Alitalo( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation: Vascular Endothelial Growth Factors (VEGF) -- Inhibition of VEGF action to control tumor angiogenesis -- VEGFs and VEGF receptor tyrosine kinases -- Structure of VEGF -- Signaling through a receptor tyrosine kinase -- Role of VEGFR-1 in angiogenesis -- Biological role of VEGF -- VEGF in embryonic angiogenesis -- Role of VEGF in physiological angiogenesis both during development and in the adult -- Roles of VEGFR-3 and VEGF-C in the early phases of development -- Mechanism of VEGF-C action in lymphatic development -- Tumor angiogenesis -- Result of overexpression of VEGF in tissues
Recombinant DNA in clinical medicine( Book )

1 edition published in 1986 in English and held by 1 WorldCat member library worldwide

The VEGF family by Kari Alitalo( Book )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Recombinant DNA in clinical medicine( Book )

1 edition published in 1986 in English and held by 1 WorldCat member library worldwide

Intermedica : 25th IFMSA anniversary issue 1976( Book )

1 edition published in 1976 in English and held by 1 WorldCat member library worldwide

VEGF inhibitors for anti-angiogenic therapy by Kari Alitalo( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

Audio-visual presentation: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response
Geeni by Ismo Ulmanen( Book )

1 edition published in 1995 in Finnish and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.69 (from 0.52 for VEGF inhib ... to 0.99 for Virustauti ...)

Alternative Names
Alitalo, K. K.

Alitalo, Kari.

Kari Alitalo Biologist, medical researcher

Kari Alitalo finnischer Mediziner

Kari Alitalo Finnish research professor (Academy of Finland), director of Translational Cancer Biology research program (AlitaloLab, Institute of Biomedicine, University of Helsinki) and director of Wihuri Research Institute (Helsinki)

Kari Alitalo Fins moleculair bioloog

Kari Alitalo finsk forsker

Kari Alitalo suomalainen akatemiaprofessori, translationaalisen syöpäbiologian tutkimusohjelman johtaja ja Wihurin tutkimusinstituutin johtaja

Languages